Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7293964 | 0.83 | GAA (0.58) | GAAEPHX2L3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL6637761 | 0.82 | ALDH1A1 (0.56) | GAAMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL19176882 | 0.82 | GAA (0.66) | GAAEPHX2L3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL770934 | 0.80 | CYP3A4 (0.87) | GAAEPHX2L3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL7166881 | 0.79 | GAA (0.62) | GAAEPHX2L3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL29313120 | 0.79 | GAA (0.62) | GAAEPHX2L3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL28856870 | 0.79 | L3MBTL1 (0.64) | GAAEPHX2L3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL557056 | 0.79 | SLC1A1 (0.67) | GAAEPHX2L3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL7912375 | 0.79 | EPHX2 (0.81) | GAAEPHX2L3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL15006781 | 0.79 | TRPV1 (0.57) | GAAEPHX2CYP3A4CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1380585-B1 | Pyrazolopyridinone as intermediate | PFIZER PROD INC (US) | 2004-11-10 | — | — | EP | disclosed |
| EP-1380585-A1 | Pyrazolopyridinone | Pfizer Products Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-1048667-B1 | Process for preparing 8-cyclopentyl-6-ethyl-3-(substituted)-5,8-dihydro-4H-1,2,3A,7,8-pentaaza-as-indacenes and intermediates useful therein | PFIZER PROD INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-6326495-B2 | HEATING A MIXTURE OF CAPROLACTONE AND P-METHOXYBENZYLAMINE; CYCLIZATION | PFIZER INC. | 2001-12-04 | — | — | US | disclosed |
| US-20010039347-A1 | Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4h-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein | PFIZER PRODUCTS INC. | 2001-11-08 | — | — | US | disclosed |
| EP-1048667-A1 | Process for preparing 8-cyclopentyl-6-ethyl-3-(substituted)-5,8-dihydro-4H-1,2,3A,7,8-pentaaza-as-indacenes and intermediates useful therein | Pfizer Products Inc. (US) | 2000-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039347-A1 | Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4h-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein | ADH1A, ADH1C, OTC | GAA 3476/4885EPHX2 1502/4885L3MBTL1 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.